Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal Intergroup Pancreatic Cancer Task Force.
This article summarizes the results of recent studies using newer agents, including farnesyl transferase inhibitors, matrix metalloproteinase inhibitors, inhibitors of the epidermal growth factor pathway, antiangiogenic therapeutics by inhibition of vascular endothelial growth factor, and some forms of immunotherapy. Although some results have been disappointing, others seem to be promising, serving as a basis for planned larger trials.
Jafari
Mehrdad
M
University of Oklahoma Cancer Center, 920 Stanton L. Young Boulevard, Oklahoma City, OK 73104, USA.
Abbruzzese
James L
JL
D000328:Adult; D026683:Advisory Committees; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002173:Cancer Care Facilities; D017024:Chemotherapy, Adjuvant / Q000639:trends; D003131:Combined Modality Therapy; D005260:Female; D005544:Forecasting; D005770:Gastrointestinal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010180:Pancreatectomy / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D018714:Radiotherapy, Adjuvant / Q000639:trends; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome